Ivacaftor

艾伐卡托

Report date: 2025/11/18 14:57:36
NMEFirst In Class

Base Information

Drug NameIvacaftor
Drug Alias NameIvacaftorum伊伐卡托依伐卡托IVAKalydeco +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator stimulants
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveCystic FibrosisSinusitis +[4] 
Global Approved IndicationsCystic Fibrosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/01/31
Country/TerritoryCzechiaBelgiumCanada +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals IncorporatedCystic Fibrosis Foundation Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesCystic Fibrosis Foundation TherapeuticsVertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (Ireland) Ltd +[4] 
Inactive CompaniesMedical University Of South CarolinaGalapagos Nv
Active IndicationsPulmonary Disease, Chronic ObstructiveCystic FibrosisSinusitis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeR07AX02
Related LinksWikipediaDrugBankKEGG